Introduction
The introduction of autologous stem cell transplantation and novel agents such as the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide has significantly improved survival of myeloma patients. 1 However, the majority of myeloma patients ultimately develop refractory disease, underscoring the need for new therapeutic approaches. The search for new strategies has led not only to the development of second-generation immunomodulatory drugs (IMiDs) and proteasome inhibitors, but also to compounds with different mechanisms of action, such as histone deacetylase inhibitors, Akt inhibitors and mTOR inhibitors. In addition, the successful application of immunotherapeutics such as the anti-CD20 monoclonal antibody (mAb) rituximab, the anti-CD52 mAb alemtuzumab and, most recently, the anti-CD30-drug conjugate brentuximab vedotin in non-Hodgkin's lymphoma, Hodgkin's lymphoma and chronic lymphocytic leukemia has stimulated the development of mAbs applicable for myeloma treatment. Interestingly, 32% of the myeloma patients achieved a partial response (PR) or stable disease following rituximab therapy. All these patients expressed CD20 on their myeloma cells. 2 However, as only B15-20% of all myeloma patients express CD20 on their bone marrow plasma cells, new targets for immunotherapy need to be identified. The search for other targets has led to the development of mAbs targeting growth factor receptors or adhesion molecules on myeloma cells. Other newly developed mAbs are directed against cellular or non-cellular components of the bone marrow microenvironment, resulting in the neutralization of growth factors, inhibition of angiogenesis, modulation of mediators of bone disease and enhancement of the host antitumor immune response ( Figure 1 and Table 1 ).
Besides direct effects via modulation of the activity of the targeted antigen, mAbs can also induce tumor cell death via complement-dependent cytotoxicity (CDC) and antibodydependent cell-mediated cytotoxicity (ADCC) (Figure 2 ). The process of ADCC is achieved through activation of Fc receptors on myeloid and natural killer (NK) effector cells by tumor cellattached immunoglobins. Subsequent cytotoxicity is mediated through at least two different mechanisms: one involving the release of perforin and granzymes from effector cells, and the other involving death ligands Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). CDC is dependent on the interaction of the antibody Fc domains with the classic complement-activating protein C1q. There is also evidence that uptake of antibody-opsonized tumor cells and cellular fragments by antigen-presenting cells is associated with enhanced antigen presentation, leading to tumor-specific T-cell responses. 3 The capability of IMiDs to activate multiple arms of the patient's immune system including enhanced ADCC 4, 5 combined with the modulation of various important signaling cascades in myeloma cells by both bortezomib and IMiDs forms the rationale to combine these novel agents with mAbs as new treatment strategies for myeloma patients. In this review, we will give an overview of various classes of mAbs at different stages of clinical development (Table 1) . mAbs with similar mechanisms of action are grouped together. Special focus will be on mAbs that are currently being evaluated in clinical trials and on combinations of these mAbs with IMiDs (Table 2) or bortezomib (Table 3) .
mAbs targeting proteins involved in myeloma cell adhesion
Myeloma cells interact with various cellular and non-cellular components of the bone marrow microenvironment, which promotes tumor growth, protects against antimyeloma agents, leads to bone destruction and increases susceptibility to infections by impairing the immune system. 6 Adhesion is mediated by cellular receptors and results in the activation of important signaling cascades in both the myeloma cell and stromal cell, leading to protection against apoptosis and increased production of several myeloma growth factors, including interleukin-6 (IL-6), insulin growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF). Over the past few years, various mAbs targeting adhesion molecules present on myeloma cells showed great promise in both preclinical and early clinical studies.
CS1
CS1 is a cell surface glycoprotein involved in myeloma cell adhesion to bone marrow stromal cells. 7, 8 High expression of CS1 has been observed in multiple myeloma cell lines and in the majority of myeloma cells from patients (CS1 mRNA expressed by more than 97% of myeloma cells), whereas CS1 is not detected at significant levels in normal tissues. 7, 8 Elotuzumab (HuLuc63), a humanized mAb that binds to CS1, inhibits myeloma cell adhesion to the bone marrow stromal cells, which results in the inhibition of the stimulatory effects of bone marrow stromal cells on myeloma cell growth and survival. 7, 8 In addition, elotuzumab was found to induce myeloma cell death through ADCC. 7, 8 Elotutuzumab exerted significant antimyeloma activity in mouse models. 7, 8 Pretreatment of effector cells with lenalidomide significantly increased elotuzumab-induced lysis of myeloma cells through stimulation of NK cell activity. 7 Also, pretreatment of myeloma cells with lenalidomide, bortezomib, dexamethasone or Akt inhibitor perifosine enhanced elotuzumab-mediated ADCC against myeloma cells.
7,9 Furthermore, the combination of elotuzumab plus bortezomib resulted in improved antitumor activity in a mouse model.
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Preliminary results from ongoing trials show encouraging results with acceptable toxicity for elotuzumab combination therapy. No dose-limiting toxicity (DLT) was reported in a phase 1 study evaluating elotuzumab 5, 10 or 20 mg on days 1, 8, 15 and 22 of a 28-day cycle in combination with lenalidomide and dexamethasone. In this study of mostly lenalidomide-naïve patients, at least PR was achieved in 82% of patients. 10 In a phase 2 trial in lenalidomide-naïve myeloma patients with a median of two previous therapies, the combination of elotuzumab and lenalidomide plus dexamethasone was feasible with 85% at least PR. 11 Two ongoing phase 3 trials will provide additional data to define the value of addition of elotuzumab to lenalidomide/dexamethasone in relapsed/refractory and newly diagnosed myeloma. The combination of elotuzumab with bortezomib was evaluated in a phase 1 study. Again no DLT occurred, and at least PR was achieved in 48% of patients, including patients with bortezomib-refractory disease. 12 Elotuzumab infusion-related side effects included dizziness, nausea and headache. 
Syndecan-1 (CD138)
Syndecan-1 (CD138) is a cell surface protein, which is expressed on normal and malignant plasma cells. 13 CD138 is not expressed by other hematopoietic cells, but expression has been noted in epithelia of several organs and in renal tubules 
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Notch -1   NF-κB   IL-6, IGF-I,  VEGF, WNT   TNF-α, TGF-β, IL-1β,  bFGF, IL- and medullary region. 14, 15 It functions as a receptor for the extracellular matrix molecules collagen and fibronectin. CD138 also binds via its heparan sulfate chains to various soluble extracellular molecules, including hepatocyte growth factor and fibroblast growth factor. 16 Treatment of myeloma cell lines and myeloma cells from patients with the murine mAb B-B4 covalently linked to the potent antimicrotubule agent DM1 (B-B4-DM1) resulted in cell death, also when myeloma cells were adherent to bone marrow stromal cells. The unconjugated B-B4 antibody alone had little activity. 15 The immunoconjugate also suppressed tumor growth in myeloma mouse models. 15 The anti-CD138 antibody nBT062 is a murine/human chimeric form of B-B4. Three immunoconjugates of nBT062 with DM1 or DM4 were developed, which also showed potent antimyeloma activities in vitro as well as in vivo in myeloma mouse models. 17 The most potent immunoconjugate tested was nBT062-SPBD-DM4. 17 In a dose-escalation study, this immunoconjugate (BT062) was administered once every 3 weeks in relapsed/refractory myeloma patients. DLT consisted of mucositis and the maximum-tolerated dose (MTD) was defined as 160 mg/m 2 . Preliminary data from this trial show evidence of clinical activity with disease stabilization in 13 out of 32 patients. 18 On the basis of these data, a new phase 1/2 study is initiated in which BT062 will be given in a more frequent dosing regimen.
The immunoconjugate nBT062-SPBD-DM4 also exerted synergistic activity when combined with lenalidomide and bortezomib both in vitro and in mouse models, 19 which forms the rationale for testing BTO62 in combination with novel agents in patients with relapsed/refractory myeloma.
Neural cell adhesion molecule (CD56)
Expression of CD56 (neural cell adhesion molecule) is found on several cancers including the majority of myeloma cases. Figure 2 Mechanism of action of mAbs. mAbs have direct effects on the myeloma cell via modulation of the activity of the targeted antigen. Furthermore, CDC and ADCC may contribute to mAb-induced tumor cell death. The process of ADCC is achieved through activation of Fc receptors on myeloid and NK effector cells by tumor cell-attached immunoglobins. CDC is dependent on the interaction of the antibody Fc domains with the classic complement-activating protein C1q resulting in the accumulation of C3b, which acts as an opsonin and promotes phagocytosis. C3b also binds to C3 convertase to form a C5 convertase, leading to the induction of the membrane attack complex (MAC). In addition, antibody-drug conjugates have the potential of specifically delivering drugs to the myeloma cell. In clinical trials, mAbs are often combined with the novel agents lenalidomide and bortezomib. The preclinical rationale for these combinations is the enhancement of ADCC by lenalidomide and the modulation of various important signaling cascades by both lenalidomide and bortezomib.
Cell Death
Normal plasma cells lack CD56 expression, whereas it is normally found on NK cells and a subset of T lymphocytes. 20, 21 Lorvotuzumab (IMGN901) consists of a potent cytotoxic maytansinoid (DM1; a microtubule-disrupting agent) attached to a CD56-binding mAb. Lorvotuzumab has potent activity as single agent against myeloma cell lines in the presence of stromal cells and in a myeloma mouse model. 22 In combination with lenalidomide, synergistic activity was observed in vitro and additive-to-synergistic efficacy was demonstrated in a myeloma mouse model. 23 Lorvotuzumab combined with bortezomib was found to be additive-to-synergistic against human myeloma xenografts in mice, whereas the combination in vitro showed antagonism. 23 A phase 1 study with CD56-positive relapsed/refractory myeloma patients showed that the MTD of lorvotuzumab was 112 mg/m 2 , with DLT consisting of fatigue and renal failure. Overall lorvotuzumab was well tolerated and had antimyeloma activity (XMR: 18%). 24, 25 This trial and the preclinical studies supported investigations of lorvotuzumab as part of a combination regimen. An ongoing phase 1 study is evaluating the combination of lorvotuzumab with lenalidomide and dexamethasone in CD56-positive relapsed/refractory myeloma. In the first dose level, two out of three myeloma patients achieved a response (one PR and one very good PR) without serious adverse events.
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CD38
CD38 is a type II transmembrane glycoprotein with ectoenzymatic activity involved in the production of calcium-mobilizing compounds. 27 Other functions ascribed to CD38 include receptor-mediated adhesion and signaling events. 27 CD38 is highly and uniformly expressed on all myeloma cells. Under normal conditions, CD38 is expressed at relatively low levels on lymphoid or myeloid cells and in some tissues of nonhematopoietic origin. 27 Recently, a new human mAb directed against CD38, daratumumab, was developed, which induced myeloma cell killing through ADCC and CDC both in the presence or absence of bone marrow stromal cells. 28, 29 In addition, daratumumab induced apoptosis when crosslinked with anti-immunoglobulin G antibody. 29 Also in mouse models, potent antimyeloma activity for daratumumab was Table 2 Results from clinical studies evaluating a monoclonal antibody in combination with lenalidomide in relapsed/refractory multiple myeloma observed. 28, 30 Pretreatment of effector cells with lenalidomide resulted in improved daratumumab-induced ADCC in myeloma cell lines and primary myeloma cells. 31, 32 Furthermore, addition of daratumumab to bortezomib or bortezomib plus lenalidomide leads to a significant enhancement of myeloma cell killing. 32, 33 On the basis of these preclinical results, daratumumab is currently evaluated in a phase 1/2 dose finding and safety study.
Another anti-CD38 antibody is the humanized antibody SAR650984, which kills myeloma cells in vitro through direct pro-apoptotic activity, CDC and ADCC. 34 In addition, in a mouse model it had strong antimyeloma activity as a single agent 34, 35 and synergistic activity when combined with melphalan. 36 SAR650984 is being evaluated in a phase 1 doseescalation trial to establish its MTD and DLT in patients with various types of CD38-positive hematological malignancies including myeloma.
ICAM-1 (CD54)
Intercellular adhesion molecule-1 (ICAM-1) mediates adhesion of myeloma cells to bone marrow stromal cells and thereby contributes to cell adhesion-mediated drug resistance. ICAM-1 is highly expressed on the plasma cell surface in the majority of myeloma patients, but is also expressed on normal cell types, including endothelial cells, epithelial cells, fibroblasts and several types of leukocytes. 37 Expression of ICAM-1 on myeloma cells increases after chemotherapy and high levels of ICAM-1 predict poor response to therapy in chemo-naïve patients. 37 BI-505 is a fully human immunoglobulin G1 antibody specific for ICAM-1 that kills myeloma cells in vitro through induction of ADCC and apoptosis when crosslinked. In addition, BI-505 inhibits myeloma tumor growth in mice. 38 On the basis of these data, a phase 1 dose-escalation study is currently recruiting relapsed/refractory myeloma patients to evaluate efficacy and toxicity of single-agent BI-505.
mAbs neutralizing growth factors or inhibiting growthpromoting receptors
Bone marrow stromal cells, endothelial cells, osteoclasts and osteoblasts produce several myeloma growth factors, which after binding to their receptors lead to the activation of signaling pathways mediating growth, survival and resistance to antimyeloma drugs. Various mAbs have been developed that neutralize growth factors or inhibit the function of their receptors.
IL-6 and IL-6 receptor
IL-6 is predominantly produced and secreted by bone marrow stromal cells and is a major growth and survival factor for myeloma cells through activation of various signaling cascades, including Table 3 Results from clinical studies evaluating a monoclonal antibody in combination with bortezomib in relapsed/refractory multiple myeloma JAK/STAT3, Ras/MAPK and PI3K/Akt. 6 IL-6 also protects against various antimyeloma agents including dexamethasone. 6, 39 Murine anti-IL-6mAbs have been used in the treatment of myeloma patients, without major side effects and with some evidence of clinical activity. 40, 41 However, in a randomized trial performed by the IFM group, addition of the murine anti-IL6mAb, B-E8, to a tandem transplantation program had no effect on overall or event-free survival. 42 In addition, rapid development of antibodies to mouse immunoglobulins results in rapid clearance and diminished efficacy of murine anti-IL-6mAbs. 40, 41 This led to the development of a chimeric mAb that neutralizes IL-6 (siltuximab; CNTO 328). Treatment of IL-6-dependent cell lines with CNTO 328 resulted in a dosedependent inhibition of proliferation both in the presence and absence of bone marrow stromal cells. 43 However, proliferation of IL-6-independent cell lines was less influenced by treatment with CNTO 328. 43 Clinical activity of this anti-IL-6mAb as single agent in myeloma patients was limited, 44, 45 which resulted in the evaluation of combinations of CNTO 328 with other antimyeloma agents.
Bortezomib activates various pro-apoptotic programs in myeloma cells, but may also lead to the activation of the antiapoptotic heat-shock protein response 46 and accumulation of the antiapoptotic protein Mcl-1.
47 IL-6 is involved in the transcriptional regulation of Mcl-1, heat-shock protein-70 and heat-shock protein-90, 43 which formed the rationale of testing CNTO 328 in combination with bortezomib. The cytotoxicity exerted by this combination in IL-6-dependent and -independent myeloma cell lines was higher than the cytotoxicity of either agent alone. 43 Combined effects were associated with reduction of bortezomib-mediated induction of Mcl-1 and heat-shock protein-70. 43 CNTO 328 also increased the cytotoxicity of dexamethasone in IL-6-dependent and -independent myeloma cell lines. Interestingly, addition of bortezomib to CNTO 328 plus dexamethasone further enhanced the cytotoxicity of the combination. 48 Furthermore, blocking IL-6 signaling by CNTO 328 increased the antimyeloma effects of melphalan in a synergistic manner. 49 On the basis of these preclinical data together with the acceptable safety profile of CNTO 328 monotherapy in myeloma, 45 the combination of CNTO 328 with bortezomib was evaluated in a phase 2 trial with bortezomib-naïve relapsed/refractory myeloma patients with a median of two prior lines of therapy. At least PR was achieved in 57% of the patients, 50 which suggests a trend for a better response rate than would have been expected with bortezomib alone in relapsed/refractory myeloma. 51 On the basis of these results, a randomized phase 3 study with bortezomib/dexamethasone with CNTO 328 or placebo has started enrolling relapsed/refractory myeloma patients. There is also another randomized trial recruiting patients, which compares the activity of CNTO 328 combined with VMP (bortezomibmelphalan-prednsione) to that of VMP alone in newly diagnosed myeloma patients.
Other agents inhibiting IL-6 signaling in preclinical stages of development include the fully humanized anti-IL-6 mAb 1339 52 and two humanized anti-IL-6 receptor mAbs, hPM1 53, 54 and tocilizumab. 55, 56 Insulin-like growth factor-1 receptor IGF-1 is another important growth and survival factor for myeloma cells, through activation of PI3K/Akt and Ras/MAPK signaling pathways. 6 Importantly, IGF-1 also protects myeloma cells against anticancer drugs including bortezomib. 57 IGF-1 receptor (IGF-1R) gene is not expressed by normal B cells or plasma cells, whereas expression of this gene is observed in myeloma cells from 31 to 50% of untreated patients. 58 The murine anti-IGF-1R mAbs mAVE1642 (ref. 59) and a-IR3
(ref. 57) impair IGF-1R signaling and growth of myeloma cells. However, the expected human anti-mouse antibody response limits the use of these murine mAbs in the clinic, and resulted in the generation of human or humanized anti-IGF-1R mAbs.
The humanized anti-IGF-1R mAb AVE1642 inhibits growth and strongly enhanced bortezomib-induced apoptosis in CD45-negative myeloma cell lines, but not in CD45-positive cell lines. 60 The mechanism of synergy between AVE1642 and bortezomib may be related to synergistic upregulation of Noxa, which induces the release of the BH3-only activators that are responsible for Bax activation. 60 On the basis of these results and phase 1 data, which showed good tolerability of AVE1642 in advanced myeloma (except for grade 3 hyperglycemia in diabetic patients), 61 the combination of AVE1642 and bortezomib was tested in relapsed/refractory myeloma. Although this combination was well tolerated, response rate was low with at least PR in only 18% of patients. 62 Figitumumab (CP-751,871) is another fully human anti-IGF-1R mAb in early clinical testing, which blocks IGF-1-induced signaling cascades and inhibits tumor growth both as single agent and more efficaciously in combination with chemotherapeutic agents in several human tumor xenograft models. 63 These results led to a phase 1 dose-escalation trial in relapsed/ refractory myeloma patients with figitumumab as single agent, but with dexamethasone added when less than PR was achieved. 64 No DLTs were identified. Monotherapy led to disease stabilization in some patients, but objective responses were not observed. The addition of dexamethasone resulted in at least MR in 33% of the patients, including dexamethasonerefractory patients. 64 Finally, promising preclinical results were obtained with the fully human anti-IGF-1R antibody IMC-A12, which inhibits tumor growth in mouse models as single agent and in combination with melphalan and bortezomib. 65 
Vascular endothelial growth factor
Myeloma cells and bone marrow stromal cells produce several pro-angiogenic factors such as VEGF, resulting in increased bone marrow angiogenesis contributing to myeloma growth and survival. In addition to the antiangiogenic effects, VEGF also functions as a growth factor for myeloma cells, stimulates IL-6 production in stromal cells, triggers myeloma cell migration and inhibits maturation of dendritic cells. Altogether, this may explain the poor survival in myeloma patients with elevated levels of VEGF. 66 Preclinical studies demonstrated that VEGFneutralizing mAbs, such as the humanized mAb bevacizumab (Avastin), inhibit activation of signaling cascades in myeloma cells, 67 reduce myeloma cell 68 and endothelial cell proliferation 69 and inhibit capillarogenesis. 69 IMiDs also have antiangiogenic effects through downregulation of factors such as VEGF, tumor necrosis factor-a (TNF-a) and basic fibroblast growth factor. This formed the rationale to evaluate the combination of bevacizumab, lenalidomide and dexamethasone in lenalidomide-naïve relapsed/refractory myeloma patients. 70 At least PR was achieved in 70% of the patients, which is not statistically superior to lenalidomide-dexamethasone alone. 71, 72 In this study, achieving CR was associated with low plasma levels of macrophage inflammatory protein-1a and VEGF. 70 In the same way, the combination of thalidomide with bevacizumab yielded similar results when compared to singleagent thalidomide. 73 Another ongoing randomized controlled phase 2 study is currently evaluating the combination of bevacizumab and bortezomib versus bortezomib and placebo. This study is based on in vitro additive antimyeloma activity between bortezomib and VEGF small interfering RNA silencing. 68 
B-cell activating factor
B-cell activating factor (BAFF) is a TNF superfamily member and produced in the bone marrow microenvironment by monocytes, osteoclasts and neutrophils. 74 Binding of BAFF to the three different TNF-R-related receptors, TACI, BCMA and BAFF-R, triggers activation of NF-kB, PI3K and MAPK pathways, resulting in survival and dexamethasone resistance of myeloma cells. 75, 76 BAFF also promotes adhesion of myeloma cells to bone marrow stromal cells. 77 In a mouse model, an anti-BAFF-neutralizing antibody had antimyeloma activity and inhibited osteoclastogenesis. 75 On the basis of these results, a phase 1 study is currently enrolling relapsed/refractory myeloma patients to evaluate the combination of the neutralizing anti-BAFF antibody, LY2127399, combined with bortezomib.
CD74
CD74 (invariant chain, Ii) associates with the major histocompatibility class IIa and b chains and directs the transport of these complexes to endosomes and lysosomes. 78, 79 CD74 also functions as a receptor for macrophage migration-inhibitory factor. 80 Binding of macrophage migration-inhibitory factor to CD74 leads to proliferation and survival of cells through activation of signaling cascades including the NF-kB pathway. [81] [82] [83] CD74 is expressed on the majority of myeloma cells in B90% of the patients. 84 In addition to its expression on antigen-presenting cells, it has restricted expression in normal human tissues. 84 Crosslinked milatuzumab (hLL1, IMMU-115), a humanized anti-CD74 mAb, blocks CD74 and thereby prevents NF-kB activation, resulting in growth-inhibitory effects and induction of apoptosis in myeloma cell lines. 85, 86 Milatuzumab lacks CDC or ADCC activity. 86 In a myeloma mouse model, treatment with milatuzumab resulted in significant survival extensions without the need for an exogenous crosslinking agent. 85, 86 Doxorubicin conjugated to this antibody (IMMU-110) had cytotoxic effects on myeloma cells in vitro and inhibited tumor growth in a mouse model without significant toxicity. 87 Also the immunotoxin, 2L-Rap-hLL1-g4P, composed of frog RNase fused to the anti-CD74 antibody killed myeloma cells in vitro. 88 Interestingly, crosslinked milatuzumab enhances the efficacy of bortezomib, doxorubicin or dexamethasone in vitro. 85 Furthermore, in a myeloma mouse model combining milatuzumab and bortezomib increased survival significantly compared with either treatment alone. 85 The observation that in a subset of myeloma patients constitutive NF-kB activity is refractory to inhibition by bortezomib 89 may be the explanation for the synergism between these two differentially acting NF-kB inhibitors. In a phase 1 trial, milatuzumab as single agent showed no severe adverse effects in relapsed/refractory myeloma patients and it stabilized the disease in some patients for up to 12 weeks. 90 The doxorubicin conjugate of milatuzumab is currently being evaluated in relapsed/refractory myeloma.
CD40
CD40 is a member of the TNF receptor family and normally expressed on B cells, dendritic cells, several types of epithelial cells and endothelial cells. In addition, it has a relatively high expression on the majority of myeloma cells. 91, 92 Upon CD40-CD40L interaction, myeloma proliferation and migration are induced via the PI3K/AKT/NF-kB signaling pathway. 93 CD40 stimulation is also important for adhesion of myeloma cells to bone marrow stromal cells, leading to increased production of IL-6 and VEGF in both cell populations. 92, 94, 95 Dacetuzumab (SGN-40) is a humanized partially agonistic anti-CD40 antibody, which induces ADCC against CD40-postive myeloma cells. 96 Although dacetuzumab does not block CD40L-induced signaling, it upregulates cytotoxic ligands such as Fas ligand and TRAIL, and downregulates expression of the IL-6 receptor, resulting in synergistic killing of myeloma cells in combination with the protein synthesis inhibitor cycloheximide. 97 Also, addition of lenalidomide to dacetuzumab enhanced cytotoxicity against myeloma cells. This was mediated via both direct antiproliferative and apoptotic effects, as well as increased sensitivity of myeloma cells to ADCC by NK effector cells. 98 In a phase 1 dose-finding study with relapsed/refractory myeloma patients (median 5 lines of prior therapy), the MTD of dacetuzumab as single agent was 12 mg/kg per week with intrapatient dose escalation to prevent cytokine release syndrome. 99 Although dacetuzumab as a single agent was generally well tolerated, no objective clinical responses were reported. 99 On the basis of the promising in vitro findings, the combination of dacetuzumab with lenalidomide and dexamethasone was evaluated in a phase 1b dose-escalation study in patients with relapsed/refractory myeloma with a median of 4 prior treatments. The combination was well tolerated and the MTD was not reached. At least PR was achieved in 39% of patients, including responses in lenalidomideexposed patients. 100 Another dose-escalation study is evaluating dacetuzumab and bortezomib in the setting of relapsed/ refractory disease.
XmAbCD40 is another humanized mildly agonistic anti-CD40 antibody with mutations in its Fc domain leading to increased FcgR binding. This Fc-engineered anti-CD40mAb had markedly increased ADCC activity against myeloma or lymphoma cells, when compared to the native immunoglobulin G1 analog. This translated into a higher efficacy of XmAbCD40 to inhibit tumor growth in mice. 101 Finally, there is a fully human antagonistic anti-CD40 mAb lucatumumab (HCD122; CHIR-12.12), which blocks CD40L-mediated signaling, inhibits CD40L-induced IL-6 and VEGF secretion in myeloma and stromal cells, and reduces CD40L-triggered myeloma cell adhesion to fibronectin or stromal cells. This results in the inhibition of CD40L-induced growth of myeloma cells in the presence or absence of stromal cells. 102 In addition, lucatumumab is a potent mediator of ADCC. 102 Preliminary data from a phase 1 study in patients with relapsed/ refractory myeloma showed that lucatumumab as a single agent was well tolerated, with one out of nine patients achieving PR and two with stable disease. The MTD was not (yet) reached and grade 1-2 toxicities mainly consisted of chills, nausea, pyrexia and arthralgia, which were most often reported during the first infusion. 103 
mAbs activating death receptors
The TNF family members Fas ligand and TRAIL induce apoptosis upon binding to the death receptors Fas, and TRAIL receptor 1 (TRAIL-R1; DR4) or TRAIL receptor 2 (TRAIL-R2; DR5), respectively. 104, 105 TRAIL also binds to the decoy receptors DcR1 and DcR2 and to the soluble decoy receptor osteoprotegerin (OPG), which is produced by osteoblasts and stromal cells. In this section, we will discuss TRAIL receptor antibodies, which have been evaluated in myeloma patients.
TRAIL-R1 and -R2
Antimyeloma activity was observed for the fully human agonistic antibody directed against TRAIL-R1 (mapatumumab, HGS-ETR1) and to a lesser extent for the anti-TRAIL-R2 antibody (lexatumumab, HGS-ETR2). 106 Importantly, the antimyeloma effect of anti-DR4 and anti-DR5 antibodies was not affected by the presence of cells of the bone marrow microenvironment, whereas these cells protected myeloma cells against TRAILinduced apoptosis. 107 This protective effect was at least partly mediated by OPG. 107 Bortezomib treatment is associated with the upregulation of TRAIL and its receptors in B-CLL and lymphoma cells. 108 Furthermore, blockage of TRAIL-R1 and -R2 expression using RNA interference, which prevents TRAIL apoptotic signaling, inhibited proteasome inhibitor-induced apoptosis. 108 Indeed, combined bortezomib plus mapatumumab treatment resulted in enhanced myeloma cell killing when compared to either agent alone, in both wild-type and bortezomib-resistant cells. 109 In contrast with the preclinical data, a randomized phase 2 study in relapsed/refractory myeloma showed that addition of mapatumumab to bortezomib treatment did not increase response rate or progression-free survival compared to bortezomib alone. 110 There was no evidence that the anti-TRAIL-R1 antibody exacerbated the toxicities associated with bortezomib. 111 NK cell effector function is regulated by multiple types of activating and inhibitory receptors that recognize ligands expressed on potential target cells. 112 NK cell cytotoxicity is incited when a target cell abundantly expresses ligands for activating receptors while few or no major histocompatibility class I ligands for inhibitory receptors, such as the killer immunoglobulin-like receptors (KIR), are expressed. Importantly, this NK versus myeloma effect diminishes during disease progression through various mechanisms including upregulation of inhibitory ligands such as PD-L1 113 and shedding of soluble forms of activating ligands like major histocompatibility complex class I-related chain A. 114 Various approaches including IMiDs, 111, 115 mAbs and cytokines such as IL-2 116 target the NK cell to improve its ability to induce myeloma cell death.
In addition, suppression of myeloma-specific cytotoxic T cells by cytokines, such as TGF-b, recruitment of regulatory T cells and altered expression of immune suppressor molecules on myeloma cells or immune effector cells, also contributes to immune evasion in myeloma. Furthermore, the function of dendritic cells is severely impaired in myeloma, including reduced expression of co-stimulatory molecules. 4 Here, we will review mAbs that are currently evaluated in myeloma patients, which reverse resistance to immune-mediated destruction of myeloma cells.
KIR
A fully human anti-KIR antibody directed against KIR2DL1/2/3 was developed (1-7F9 or IPH2101), which blocks the interactions with their HLA-C ligands and thereby enhances NK cell activity. Collectively, the inhibitory KIR2DL1, -2 and -3 receptors recognize essentially all HLA-C allotypes. 117 Cytotoxicity of both purified NK cells and isolated peripheral blood mononuclear cells against myeloma cell lines was enhanced by 1-7F9. 118 Combination therapy of lenalidomide, which also activates NK cells, with 1-7F9 resulted in increased NK cell cytotoxicity directed towards the myeloma cells when compared to treatment with either agent alone. 118 Potential mechanisms for the enhancement of NK cell activity against myeloma cells by the combination of lenalidomide and 1-7F9 include increased NK cell migration to myeloma cells, upregulation of several NK cell activating ligands and increased interferon-g and granzyme B production by the NK cells. 119 Preliminary results from a dose-escalation study in patients with relapsed/refractory myeloma showed that 1-7F9/IPH2101 as a single agent is well tolerated. Objective responses were not observed; however, some patients achieved stabilization of disease. 120 Antitumor activity and toxicity of single-agent 1-7F9 will also be determined in smoldering myeloma patients and in patients who achieved a stable PR or very good PR following first-line therapy. The hypothesized synergistic activity of lenalidomide and 1-7F9 is currently being evaluated in a phase 1/2 trial with relapsed/refractory myeloma patients.
PD-L1
Another way of improving antitumor activity of NK cells against myeloma cells is by modulating the PD-1/PD-L1 axis, which downregulates the immune response.
121 PD-1 is not present on NK cells from healthy donors, but can be upregulated by exogenous IL-2. 113 In contrast, PD-1 is present on NK cells from patients and interaction with PD-L1 on myeloma cells inhibits NK cell function. 113 PD-L1 is expressed on plasma cells from the majority of myeloma patients, but only rarely on plasma cells from MGUS patients and not on normal plasma cells. 122 CT-011 is a humanized anti-PD-1 mAb, which enhanced NK cell function against myeloma tumor cells through increased NK cell trafficking, improved immune complex formation between myeloma cells and NK cells, and increased NK cell cytotoxicity. Lenalidomide not only activates NK cells, but also downregulates PD-L1 expression on myeloma cells and synergized with CT-011 in the activation of NK cells and subsequent killing of myeloma cells. 113 Apart from effects on NK cells, blockade of the PD-1/PD-L1 interaction with anti-PD-L1 mAbs enhanced myeloma-specific T-cell immunity in vitro and in vivo. 122, 123 Furthermore, CT-011 also enhanced T-cell responses to autologous dendritic cell/myeloma fusion vaccines. 124 This may be explained by increased expression of PD-1 on T cells from myeloma patients when compared to healthy controls.
On the basis of these data, a phase 1 clinical trial was initiated to study the effect of CT-011 in patients with advanced hematological malignancies including myeloma patients. CT-011 was demonstrated to be well tolerated with evidence of antitumor activity. Treatment with CT-011 was accompanied with an elevated percentage of peripheral blood CD4-positive T cells. 125 The combination of CT-011 with an IMiD may further enhance host antitumor immunity and warrants further investigation. Alternatively, the immune response to myeloma may be enhanced by anti-PD-L1 antibodies such as MDX-1105.
CD200
CD200 is expressed on B and T lymphocytes, endothelial cells, dendritic cells and neurons, but normal plasma cells lack CD200 expression. 126 However, the majority of myeloma patients have CD200 expression on their tumor cells, which correlated with shorter survival after autologous stem cell transplantation, 126, 127 possibly explained by the CD200-mediated suppression of the cytotoxic T-cell immune response leading to tumor immune evasion.
Samalizumab (ALXN6000) is a humanized immunoglobulin G2/4 anti-CD200 antibody, which blocks CD200-CD200R interactions without ADCC or CDC activity. In mouse models, this antibody improved peripheral blood mononuclear cellmediated tumor growth inhibition in CD200-positive tumors. 128 In a phase 1/2 study, single-agent samalizumab was evaluated in patients with myeloma or chronic lymphocytic leukemia. Treatment was well tolerated with antitumor activity evident in some patients receiving multiple cycles, which was associated with reduction in regulatory T cells and increase in activated T cells. 129 
mAbs targeting mediators of bone disease
More than half of the myeloma patients present with bone disease at diagnosis. Increased osteoclastogenesis and osteoclast activation combined with reduced osteoblastogenesis and impairment of osteoblast function result in the development of osteolytic bone lesions. Importantly, osteoclast activity may also contribute to myeloma cell growth and survival, 130 whereas osteoblasts may inhibit myeloma cell growth. 131, 132 Bisphosphonates impair osteoclast activity and thereby reduce (but not completely prevent) skeletal complications. However, bisphosphonates are unable to induce bone formation and repair of lytic lesions. Therefore, new treatment approaches are needed. Multiple mediators that lead to the severe imbalance between increased osteoclastic bone resorption and decreased bone formation have been identified, leading to the development of several mAbs for the treatment of myeloma bone disease. Two of these mAbs, denosumab and BHQ880, are in clinical development.
Receptor activator of the NF-kB ligand (RANKL) is present on myeloma cells and can be induced on stromal cells by myeloma cells. Interaction of RANKL with RANK leads to increased osteoclastogenesis and activation of osteoclasts. OPG inhibits RANK/RANKL interactions and myeloma cells reduce its production by osteoblasts and stromal cells. The critical role of the OPG/RANKL/RANK system for the development of myeloma bone has been demonstrated by using recombinant OPG, RANK-Fc or anti-RANKL antibodies. These preclinical studies not only demonstrated inhibition of skeletal destruction, but also decrease in tumor burden. 130, [133] [134] [135] In a phase 2 trial with myeloma patients, denosumab, which is a fully human neutralizing anti-RANKL mAb, suppressed the RANKL pathway as evidenced by reductions in bone turnover markers. Denosumab was well tolerated, but no objective antitumor responses were observed. 136 Recently, a phase 3 study demonstrated that denosumab was non-inferior to zoledronic acid in preventing or delaying skeletal-related events in patients with solid tumors or myeloma. Patients treated with denosumab experienced a greater suppression of bone turnover markers than with zoledronic acid. 137 Production of the soluble Wnt inhibitor Dickkopf-1 by myeloma cells inhibits differentiation of osteoblast precursor cells, 138 which explains the association between high Dickkopf-1 levels and the presence of osteolytic bone lesions. 139 The fully human Dickkopf-1-neutralizing antibody BHQ880 reversed the inhibitory effect of myeloma cells on osteoblastogenesis, stimulated bone formation, inhibited stromal cell/myeloma cell adhesion, reduced production of IL-6 by stromal cells and inhibited tumor growth both in vitro and in mouse models. 140 In the 5T2MM mouse model, BHQ880 prevented the development of osteolytic bone lesions. 141 On the basis of these preclinical studies, a phase 1/2 study was initiated in which relapsed/ refractory myeloma patients received BHQ880 in combination with zoledronic acid. This combination was well tolerated with increases in bone mineral density in several patients. 142 Combination of denosumab or BHQ880 with bortezomib would be an interesting approach, as bortezomib not only inhibits bone resorption, but also increases bone formation. 143, 144 Promising results from preclinical studies showed that mAbs targeting activin A, 145 sFRP-2 146 and macrophage inflammatory protein-1a 147, 148 hold promise as new treatment modalities for myeloma bone disease.
Concluding remarks and future perspectives
Although survival of myeloma patients has significantly increased, almost all patients will develop refractory disease. Median overall survival in patients who relapse after or are refractory to bortezomib and either thalidomide or lenalidomide is only 6 months, 149 indicating the need for new treatment strategies. At this moment, encouraging preclinical results as well as clinical data indicate that mAbs targeting growth factor receptors and adhesion molecules present on myeloma cells, or components in their surrounding microenvironment, such as growth factors, pro-angiogenic factors, mediators of myeloma bone disease and immune effector cells, are emerging as important antimyeloma agents.
In this review, we grouped together mAbs with similar mechanisms of action. However, as several mAbs have multiple effects on the tumor and microenvironment, these antibodies often belong to more than one class. For example, antibodies inhbiting VEGF inhibit tumor growth, impair angiogenesis, and given the immunesuppressive effects of VEGF may also improve immune function.
An important observation from these clinical trials is that mAbs alone have limited antitumor activity; however, combination with other antimyeloma agents is a promising new treatment strategy in myeloma. Of great interest is the combination of various therapeutic antibodies with an IMiD such as lenalidomide, which not only has potent direct antimyeloma activity, but also significantly enhances ADCC. In addition, encouraging data are available showing that the combination of a proteasome inhibitor with a mAb induces myeloma cell death in a synergistic way, through independently targeting the same pathway or via inhibition of different signaling cascades. In this respect, several mAbs are currently being evaluated in phase 2 trials in combination with other antimyeloma therapies to determine the best partner drugs for antibody-based immunotherapy in terms of disease response and toxicity. On the other hand, some mAbs including elotuzumab and siltuximab, which showed promise in phase 2 trials, have proceeded to randomized controlled phase 3 trials to define their value as adjunctive treatment to novel agents in improving survival (Table 1) . Furthermore, an increased understanding of unique properties of myeloma cells and their environment will probably lead to the design of more rational antibody-containing combination therapies that will not only target important signaling cascades in the myeloma cells, but also important extrinsic components that contribute to myeloma cell survival, such as adhesion of tumor cells to stromal cells, pro-survival signals in the microenvironment, mechanisms of immune escape and mediators of bone disease.
Such combinations will result in more effective eradication of the tumor, while at the same time drug resistance will be prevented.
A second important conclusion from this review is that although expression of mAb targets is not always restricted to the myeloma tumor cells, toxicity of the mAbs is relatively mild. On the other hand, minimizing side effects of chemotherapy can also be achieved by using myeloma-specific antibody conjugates to specifically deliver cytotoxic drugs to the tumor cells. This approach will allow the administration of lower doses of cytotoxic drugs and may therefore reduce toxicity of antimyeloma therapies. In myeloma, promising results from early clinical testing have been obtained for several antibody drug conjugates (Table 1) .
In this review, we mainly focused on mAbs that are currently under clinical evaluation or have been tested in clinical trials. However, multiple other mAbs are in various stages of preclinical development, including antibodies targeting FGFR3, [150] [151] [152] HM1.24/CD317, 153, 154 b2-microglobulin, a4-integrin (CD49d; subunit of VLA-4) 156 and PSGL-1 (Pselectin glycoprotein ligand-1; CD162). 157 Other promising agents include MDX-1097, which targets kappa light chains not associated with heavy chains present on the surface of kappapositive myeloma cells (kappa myeloma antigen), and is currently evaluated in a phase 2 trial based on promising preclinical data 158 and favourable phase 1 safety data; 159 antibody-drug conjugates binding to FcRL5; 160 an anti-IL-17A antibody that inhibits myeloma cell growth and osteoclast development; 161 and a bispecific antibody that neutralizes both VEGF and angiopoietin-2, resulting in strong inhibition of angiogenesis. 162 However, despite the enormous progress that has been made, many challenges still remain such as the unravelling of mechanisms of therapeutic resistance to mAbs. These mechanisms include changes in the expression of the targeted antigen, alterations in activity and level of complement control proteins, immune escape, protective factors in the bone marrow microenvironment and activation of compensatory signaling pathways in the myeloma tumor cells. In addition, not only tumor-related features contribute to resistance to antibody-based therapies, but also patient characteristics may be involved including FcgR genetic polymorphisms, which are linked to the ability to mount an ADCC response and to clinical outcome as demonstrated for rituximab in lymphoma patients. 163 Recently, several approaches have been developed to improve the affinity of human antibodies to the various FcgR's including engineering of the amino-acid sequence of the Fc portion of the antibody or modifying the glycosylation state of the mAb. This will result in antibodies with increased efficacy in mediating lysis of myeloma cells. Furthermore, reduced antibody-mediated tumor cell lysis may also be explained by dysfunction of immune effector cells as a result of antimyeloma therapies or interactions with myeloma tumor cells and components of the microenvironment. However, as described above, effector function of NK cells can be improved by selecting an IMiD-containing immunotherapy regimen. Increased understanding of these diverse mechanisms will probably lead to other strategies to circumvent resistance to antibody therapy in myeloma patients.
Another important challenge will be the identification of patient subsets that will benefit most from certain antibodybased therapeutics. Efficacy of mAb therapies is dependent on antigen protein expression and neutralizing mAbs are best used in tumors that are at least partly dependent on the antigen or pathway neutralized by the therapeutic mAb. Biological studies, such as flow cytometric analysis, cytogenetic analysis and probably also gene expression profiling, will result in the identification of subgroups of myeloma patients that will likely benefit from a certain antibody-based combination therapy. Future studies should incorporate analysis of biomarker components that can predict the safety and effectiveness of new mAbs.
Increased understanding of the biology of myeloma including the importance of the cross-talk between tumor cells and the microenvironment has resulted in the development of several novel therapeutic strategies including several classes of mAbs, which specifically target the myeloma tumor cell or various components of the bone marrow microenvironment. Altogether, the introduction of novel antimyeloma agents combined with the identification of biomarkers that are predictive of therapeutic responses will eventually result in a more individualized targeted therapy, which will hopefully be better tolerated and more effective, resulting in further improvement of survival of myeloma patients.
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